Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study

British Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2008, Pages 695-705

  Diav Citrin, Orna ^a   Shechtman, Svetlana ^a   Weinbaum, Dafna ^b   Wajnberg, Rebecka ^a   Avgil, Meytal ^a,b   Di Gianantonio, Elena ^c   Clementi, Maurizio ^c   Weber Schoendorfer, Corinna ^d   Schaefer, Christof ^d   Ornoy, Asher ^a,b  

^a MINISTRY OF HEALTH   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c Servizio di Informazione Teratologica   (Italy)

^d Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy   (Germany)

Author keywords

Cardiovascular anomalies; Congenital anomalies; Fluoxetine; Paroxetine; Pregnancy; SSRI

Indexed keywords

ANTIBIOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CLONAZEPAM; CLOTRIMAZOLE; DIAZEPAM; DICLOFENAC; DIPYRONE; ENOXAPARIN; ERYTHROMYCIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUOXETINE; IBUPROFEN; METRONIDAZOLE; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; PARACETAMOL; PAROXETINE; PENICILLIN DERIVATIVE; PENICILLIN V POTASSIUM; VALPROIC ACID;

ADULT; AORTA COARCTATION; AORTA VALVE STENOSIS; ARTICLE; ATTENTION DEFICIT DISORDER; BICUSPID VALVE DYSPLASIA; BIRTH WEIGHT; CARDIOVASCULAR MALFORMATION; CIGARETTE SMOKING; CLINICAL TRIAL; CLUBFOOT; CONGENITAL MALFORMATION; CONTROLLED STUDY; CORPUS CALLOSUM AGENESIS; CRANIOFACIAL SYNOSTOSIS; DRUG ELIMINATION; DRUG HALF LIFE; EBSTEIN ANOMALY; EPIGASTRIC HERNIA; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HERNIA; HUMAN; HYDROCEPHALUS; INGUINAL HERNIA; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENTAL DEFICIENCY; MITRAL VALVE DISEASE; MULTICENTER STUDY; MULTICYSTIC DYSPLASTIC KIDNEY; OBSERVATIONAL STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PATENT FORAMEN OVALE; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRUNE BELLY SYNDROME; PULMONARY ARTERY STENOSIS; PULMONARY VALVE STENOSIS; PYLORUS STENOSIS; RISK ASSESSMENT; SACROCOCCYX TERATOMA; SPONTANEOUS ABORTION; TERATOGENESIS; TERATOGENICITY; TRICUSPID VALVE REGURGITATION; TRISOMY 21; URINARY TRACT MALFORMATION;

EID: 55149097035     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03261.x     Document Type: Article

References (60)

1. Wisner KL, Peindl KP, Hanusa BH. Relationship of psychiatric illness to childbearing status: a hospital-based epidemiologic study. J Affect Disord 1993 28 : 39 50.
2. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy. JAMA 1999 282 : 1264 9.
3. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Child Psychol 1984 93 : 158 71.
4. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001 323 : 257 60.
5. Eggen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Phamacol 2004 60 : 659 66.
6. Malm H, Martikainen J, Klaukka T, Neuvonen PJ Finnish Register-Based Study. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur J Clin Pharmacol 2003 59 : 127 33.
7. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008 198 : 194.e1 5.
8. Hendrick V, Stowe Z, Altshuler L, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medication. Am J Psychiatry 2003 2003 : 993 6.
9. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormarck M, Leen-Mitchell M, Woodland C, Gardner A, Horn G, Koren G. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993 269 : 2246 8.
10. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996 335 : 1010 5.
11. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997 89 : 713 8.
12. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Matroiacovo P, Arnon J, Rodriguez-Pinilla E, Schaefer C, Pexieder T, Merlob P, Dal Verme S. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996 10 : 285 94.
13. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998 105 : 882 9.
14. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998 279 : 609 10.
15. Ericson A, Källén B, Wiholm B-E. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999 55 : 503 8.
16. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003 188 : 812 5.
17. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002 159 : 2055 61.
18. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005 106 : 1289 96.
19. Wogelius P, Nørgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sørensen HT. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006 17 : 701 4.
20. Källén B, Otterblad-Olausson P. Antidepressants drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006 21 : 221 2.
21. Källén B, Otterblad-Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007 79 : 301 8.
22. Bérard A, Ramos E, Rey E, Blais L, StAndré M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007 80 : 18 27.
23. Alwan S, Reefuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007 356 : 2684 92.
24. GlaxoSmithKline Clinical Trial Register. GlaxoSmithKline Clinical Trial Register Epidemiology Study: Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation. EPIP083 Preliminary report and updated preliminary report [online]. Available at http://ctr.gsk.co.uk/summary/paroxetine/studylist.asp (last accessed: 1 October 2007)
25. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007 356 : 2675 83.
26. Dear Health Care Professional letter, issued September, 2005 [online]. Available at http://us.gsk.com/news/paroxetine/paxil_letter_2005,e3.pdf (last accessed: 1 December 2005)
27. Dear Health Care Professional letter, issued December, 2005. Available at http://us.gsk.com/news/paroxetine/paxil_letter_2005;e3.pdf (last accessed: 1 December 2005)
28. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993 92 : 721 2.
29. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997 58 : 291 7.
30. Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Talylor NF, Fletcher AP, Schou JS. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997 53 : 163 9.
31. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001 84 : F134 5.
32. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002 156 : 1129 32.
33. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004 158 : 312 6.
34. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005 365 : 482 7.
35. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006 160 : 173 6.
36. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006 354 : 579 87.
37. Clementi M, Di Gianantonio E, Ornoy A. Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet 2002 5 : 8 12.
38. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy - 15 years experience of ENTIS. Reprod Toxicol 2005 20 : 331 43.
39. Schaefer C, Peters P, Miller RK (editors). Drugs during Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edn. London : Academic Press, an imprint of Elsevier, 2007.
40. Briggs GG, Freeman RK, Yaffe SJ (editors). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 7th edn. Philadelphia, PA : Lippincott Williams & Wilkins, 2005.
41. Diav-Citrin O, Shechtman S, Weinbaum D, Arnon J, Wajnberg R, Ornoy A. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled cohort study abstract Teratology 2002 65 : 298.
42. Diav-Citrin O, Schechtman S, Weinbaum D, Arnon J, Di Gianantonio E, Clementi M, Ornoy A. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study abstract Reprod Toxicol 2005 20 : 459.
43. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007 29 : 918 26.
44. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008 165 : 749 52.
45. Oberlander TE, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008 83 : 68 76.
46. Baldwin JA, Davidson EJ, Pritchard AL, Ridings JE. The reproductive toxicology of paroxetine. Acta Psychiatr Scand Suppl 1989 350 : 37 9.
47. Rayburn WF, Gonzalez CL, Christensen HD, Kupiec TC, Jacobsen JA, Stewart JD. Effect of antenatal exposure to paroxetine (paxil) on growth and physical maturation of mice offspring. J Matern Fetal Med 2000 9 : 136 41.
48. Byrd RA, Markham JK. Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994 22 : 511 8.
49. Yavarone MS, Shuey DL, Tamir H, Sadler TW, Lauder JM. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 1993 47 : 573 84.
50. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 2003 21 : 417 24.
51. Dayan J, Creveuil C, Herlicoviez M, Herbel C, Baranger E, Savoye C, Thouin A. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol 2002 155 : 302 4.
52. Dayan J, Creveuil C, Marks MN, Conroy S, Herlicoviez M, Dreyfus M, Tordjman S. Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med 2006 68 : 938 46.
53. Orr ST, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002 156 : 797 802.
54. Fedrick J, Alberman ED, Goldstein H. Possible teratogenic effect of cigarette smoking. Nature 1971 231 : 529 30.
55. Kelsey JL, Dwyer T, Holford TR, Bracken MB. Maternal smoking and congenital malformations: an epidemiological study. J Epidemiol Community Health 1978 32 : 102 7.
56. Himmelberger DU, Brown BW Jr., Cohen EN. Cigarette smoking during pregnancy and the occurrence of spontaneous abortion and congenital abnormality. Am J Epidemiol 1978 108 : 470 9.
57. Wasserman CR, Shaw GM, O'Malley CD, Tolarova MM, Lammer EJ. Parental cigarette smoking and risk for congenital anomalies of the heart, neural tube, or limb. Teratology 1996 53 : 261 7.
58. Kuehl KS, Loffredo CA. Population-based study of l-transposition of the great arteries: possible associations with environmental factors. Birth Defects Res A Clin Mol Teratol 2003 67 : 162 7.
59. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001 26 : 44 8.
60. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006 295 : 499 507.